Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
Citi
Chubb
Baxter
McKesson
Daiichi Sankyo
US Army
Cipla

Generated: June 18, 2018

DrugPatentWatch Database Preview

SYNRIBO Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Synribo, and what generic alternatives are available?

Synribo is a drug marketed by Teva Pharms Intl and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in nineteen countries.

The generic ingredient in SYNRIBO is omacetaxine mepesuccinate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the omacetaxine mepesuccinate profile page.
Summary for SYNRIBO
International Patents:49
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 35
Clinical Trials: 6
Patent Applications: 11
DailyMed Link:SYNRIBO at DailyMed
Drug patent expirations by year for SYNRIBO
Synonyms for SYNRIBO
(-)-homoharringtonine
(2'R,3S,4S,5R)-(-)-homoharringtonine
(2S,3S,6S)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0<2,6>.0<6,10>.0<15,1 9>]icosa-1(20),4,13,15(19)-tetraen-3-yl methyl (2R)-2-hydroxy-2-(4-hydroxy-4-m ethylpentyl)butane-1,4-dioate
1-((1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H- cyclopenta(a)(1,3)dioxolo(4,5-h)pyrrolo(2,1-b)(3)benzazepin-1-yl) 4-methyl (2R)-2- hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
26833-87-4
6FG8041S5B
AB0019750
AB00642561-02
AC1L6273
AC1Q5YWQ
ACN-035229
AKOS024456585
Ambotz26833-87-4
BRD-K76674262-001-01-7
BRN 5687925
C29H39NO9
Ceflatonin
Cephalotaxine 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester)
cephalotaxine 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
Cephalotaxine, 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester) (9CI)
Cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), (3(R))- (9CI)
Cephalotaxine, 4-methyl-, 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester)
CGX 635
CGX-635
CGX-635-14 (formulation)
CHEBI:71019
CHEMBL46286
CS-2872
CTK8E8620
D08956
D0M4XY
DB04865
GTPL7454
HMS3267H22
Homoharringtonin
homoharringtonine
Homoharringtonine (8CI)
Homoharringtonine, >=98% (HPLC)
Homoharringtonine|||Omacetaxine mepesuccinate
HY-14944
HYFHYPWGAURHIV-JFIAXGOJSA-N
mepesuccinate d'omacetaxine
mepesuccinato de omacetaxina
MFCD05618221
MLS001424293
MolPort-003-983-592
Myelostat
N1504
NC00395
NCGC00025155-01
NCGC00025155-02
NCGC00025155-03
NCGC00025155-04
NCI60_000917
NSC 141633
NSC-141633
NSC141633
o3-[(2r)-2,6-dihydroxy-2-(2-methoxy-2-oxoethyl)-6-methylheptanoyl]cephalotaxine
Omacetaxine (homoharringtonine)
Omacetaxine mepesuccinate
Omacetaxine mepesuccinate (USAN)
Omacetaxine mepesuccinate [USAN:INN]
omacetaxini mepesuccinas
Omapro
SAM001246822
SCHEMBL12745687
SMR000469230
SR-01000597562
SR-01000597562-1
ST056357
Synribo (TN)
Tekinex
TR-031859
UNII-6FG8041S5B
V0232
ZINC26011099
ZJ-C

US Patents and Regulatory Information for SYNRIBO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for SYNRIBO
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 2016-10-26

Non-Orange Book US Patents for SYNRIBO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,842,687 Cephalotaxane derivatives and their processes of preparation and purification ➤ Try a Free Trial
6,613,900 Cephalotaxane derivatives and process for their preparation ➤ Try a Free Trial
7,169,774 Cephalotaxane derivatives and their processes of preparation and purification ➤ Try a Free Trial
6,831,180 Cephalotaxane derivatives and process for their preparation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
AstraZeneca
Julphar
Deloitte
Boehringer Ingelheim
Queensland Health
Moodys
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.